跳至主要内容
临床试验/NCT04154228
NCT04154228Unknown不适用

Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI

Tel-Aviv Sourasky Medical Center0 个研究点目标入组 100 人开始时间: 2019年12月10日最近更新:
适应症

试验速览

阶段
不适用
入组人数
100
主要终点
Patients that preform 18F-FDG PET/MRI and the routinely PET/CT

研究概览

简要总结

18F-FDG PET/MR imaging protocol integrating advanced MR vascular imaging sequences, along with computerized quantitative methods for data analysis, is expected to serve as an objective tool for assessment of lymphoma patients. The aim of this prospective study is to develop an automatic artificial intelligence-based tool for the assessment of early response to treatment and evaluation of residual masses in patients with lymphoma. Specific objectives are:

  1. To evaluate the added value of 18F-FDG PET/MRI compared with PET/CT in imaging lymphoma.
  2. To optimize PET/MR imaging protocol for lymphoma assessment.
  3. To develop an automated tool for staging patients with lymphoma.
  4. To develop an automated method for early prediction of response to therapy and prognosis in patients with lymphoma.
  5. To develop an automated non-invasive tool for discriminating benign from active residual masses at end of treatment in patients with lymphoma.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • patients with newly diagnosed hodgkin's, aggressive non-hodgkin's and follicular lymphoma (for whom the PET/CT is the imaging modality of choice)/
  • Patients aged 18 years or older of both sexes.
  • Patients treated at Tel-Aviv Sourasky Medical center.

排除标准

  • contraindication to MRI or to intravenous gadolinium injection.

结局指标

主要结局

Patients that preform 18F-FDG PET/MRI and the routinely PET/CT

时间窗: 1 year

Patients that preform 18F-FDG PET/MRI and the routinely PET/CT, and the investigators optimize PET/MRI imaging protocol, and to develop an automated artificial intelligence-based tool for assessment of early response to treatment in patients with lymphoma.

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

相似试验